#1 Clinical Trials Search in Europe

Ovarian cancer – Trials in Disease

Go back

Ongoing Clinical Trials for Ovarian Cancer

This article provides information about 65 ongoing clinical trials for patients with ovarian cancer. These studies are testing new treatments and treatment combinations, including targeted therapies, immunotherapies, and chemotherapy approaches. The trials are being conducted across multiple countries in Europe and include patients at various stages of disease. (Also known as: Cancer of the Ovary, Ovarian Neoplasm, Ovarian Carcinoma)

Clinical trial locations

Comparison of Niraparib alone versus Niraparib with Bevacizumab in patients with newly diagnosed advanced ovarian cancer after chemotherapy with carboplatin and paclitaxel

This trial is comparing two maintenance treatment approaches for patients with newly diagnosed advanced ovarian, peritoneal, or fallopian tube cancer. All participants first receive standard chemotherapy with carboplatin and paclitaxel. After completing chemotherapy, patients are randomly assigned to either receive niraparib alone or niraparib combined with bevacizumab.

Main inclusion criteria: Participants must have newly diagnosed advanced high-grade serous or endometrioid ovarian, peritoneal, or fallopian tube cancer (FIGO stage IIIA to IIIC). They must have undergone complete surgery with no visible remaining disease and completed one cycle of platinum-based chemotherapy. Patients need adequate organ function including normal blood counts, liver function, and kidney function. They must be 18 years or older and have an ECOG performance status of 0-1.

Main exclusion criteria: The study excludes patients with non-high-grade serous or endometrioid cancer types, those with uncontrolled hypertension or significant cardiovascular disease, patients with active infections, and those who are pregnant or breastfeeding. Patients with major surgery within 4 weeks or recent chemotherapy within specified timeframes are also excluded.

Trial focus: The study aims to determine whether adding bevacizumab to niraparib maintenance therapy provides better outcomes than niraparib alone. The primary endpoint is progression-free survival, measuring how long patients remain without cancer progression. The trial also evaluates overall survival, quality of life, and safety of both treatment approaches.

Investigational drugs: Niraparib is a PARP inhibitor administered orally that prevents cancer cells from repairing DNA damage. Bevacizumab is an angiogenesis inhibitor given intravenously that blocks blood vessel formation to tumors. Carboplatin and paclitaxel are chemotherapy drugs given intravenously during the initial treatment phase before maintenance therapy begins.

Evaluation of COM701 as Maintenance Therapy for Patients with Relapsed Platinum-Sensitive Ovarian Cancer

This trial evaluates COM701 as a maintenance therapy for patients with platinum-sensitive recurrent ovarian, fallopian tube, or primary peritoneal cancer. The study compares COM701 treatment to placebo in patients who have completed at least two previous courses of platinum-containing therapy and have responded to their most recent treatment.

Main inclusion criteria: Participants must have platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer confirmed by tissue examination. They must have completed at least 2 prior lines of platinum-containing therapy and received prior maintenance therapy with bevacizumab or PARP inhibitors if eligible. Patients need to start treatment within 4 weeks after their last chemotherapy dose and have an ECOG performance status of 0 or 1.

Main exclusion criteria: The trial excludes patients with platinum-resistant disease (progression during or within 6 months of platinum therapy), those with active autoimmune diseases requiring systemic treatment, patients with uncontrolled infections or certain heart conditions, and those who are pregnant or breastfeeding. Patients with other active cancers or recent major surgery are also excluded.

Trial focus: The study aims to determine whether COM701 maintenance therapy can extend progression-free survival compared to placebo in patients with platinum-sensitive recurrent ovarian cancer. Researchers will monitor how long patients remain without disease progression using standard imaging criteria (RECIST 1.1) and evaluate safety using established toxicity scales (NCI CTC-AE v5).

Investigational drug: COM701 is an immune checkpoint inhibitor administered intravenously that blocks the PVRIG pathway. By inhibiting this immune checkpoint, COM701 enhances T-cell activity, allowing the immune system to better recognize and attack cancer cells. This investigational drug represents a novel immunotherapy approach for maintaining remission in recurrent ovarian cancer.

Long-term Safety Study of Niraparib for Patients with Advanced Ovarian, Breast, or Prostate Cancer Who Completed a Previous Niraparib Study

This continuation study provides ongoing access to niraparib for patients who participated in previous niraparib trials and continue to benefit from treatment. The study monitors long-term safety and tolerability of niraparib in patients with advanced ovarian, breast, or prostate cancer who completed parent trials sponsored by GSK/TESARO.

Main inclusion criteria: Participants must be currently receiving niraparib treatment in a GSK/TESARO-sponsored study that has met its primary objectives. They must be benefiting from niraparib treatment as determined by their doctor and be willing to follow study procedures. Female participants of childbearing potential must use effective contraception during treatment and for 180 days after the last dose. Male participants must use condoms and not donate sperm during treatment and for 90 days after.

Main exclusion criteria: The study does not accept patients who are not currently participating in a parent niraparib study or those who are not benefiting from niraparib treatment. Patients unable to swallow tablets whole or who have conditions preventing oral medication use are excluded. Those who are part of vulnerable populations as defined by local regulations may also be excluded.

Trial focus: The primary objective is to evaluate the long-term safety and tolerability of continued niraparib treatment. The study monitors adverse effects, changes in clinical parameters including vital signs, physical examinations, and laboratory assessments. This extension trial ensures patients who are benefiting from niraparib can continue treatment until it becomes commercially available in their location.

Investigational drug: Niraparib is a PARP inhibitor administered orally in capsule form. It works by blocking the PARP enzyme, which helps repair DNA damage in cells. By preventing cancer cells from repairing themselves, niraparib leads to their death. It is particularly effective in cancers with BRCA mutations or homologous recombination deficiency.

Study Comparing Rinatabart Sesutecan with Other Treatments for Patients with Platinum-Resistant Ovarian Cancer

This trial compares the effectiveness of rinatabart sesutecan (Rina-S) against investigator’s choice of chemotherapy in patients with platinum-resistant high-grade serous ovarian, fallopian tube, or primary peritoneal cancer. The study evaluates whether Rina-S can improve progression-free survival compared to standard chemotherapy options.

Main inclusion criteria: Participants must have confirmed high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer that is platinum-resistant (progressed within 6 months after last platinum treatment). They must have received between 1-4 previous systemic treatments and have at least one measurable tumor lesion. Patients need adequate organ function including liver, kidney, and bone marrow function, with an ECOG performance status of 0 or 1.

Main exclusion criteria: The trial excludes patients with non-high-grade serous or endometrioid cancer types, those with active brain metastases, patients with significant cardiovascular disease or uncontrolled hypertension, and those with major surgery within 4 weeks. Patients with inadequate organ function, active infections, or who are pregnant/breastfeeding are also excluded.

Trial focus: The study aims to determine whether Rina-S treatment can extend progression-free survival compared to investigator’s choice chemotherapy (paclitaxel, doxorubicin, gemcitabine, or topotecan). Researchers will monitor disease progression using RECIST v1.1 criteria, evaluate overall survival, and assess quality of life throughout the treatment period using standardized questionnaires.

Investigational drug: Rinatabart sesutecan (Rina-S) is an antibody-drug conjugate administered intravenously. It targets folate receptor alpha (FRα) proteins commonly found on ovarian cancer cells, delivering a cytotoxic agent directly to tumor cells. This targeted approach aims to maximize cancer cell destruction while minimizing damage to healthy cells.

Study for Patients with BRCA Mutated Ovarian, Breast, Pancreatic, Prostate, and Endometrial Cancers Continuing Olaparib Treatment

This continuation study provides ongoing olaparib treatment to patients who participated in previous olaparib trials and continue to benefit from therapy. The study ensures access to olaparib for patients with BRCA-mutated cancers including ovarian, breast, pancreatic, prostate, and endometrial cancers who completed parent studies but cannot access the medication locally.

Main inclusion criteria: Participants must have provided signed informed consent and currently be benefiting from olaparib treatment in an AstraZeneca-sponsored study. They must be receiving olaparib treatment in a parent study (either open-label or blinded) and continue to derive clinical benefit as determined by their doctor. The first dose in the extension study must be within 7 days of completing the parent study treatment interruption window.

Main exclusion criteria: The study excludes patients who are not currently participating in an olaparib parent trial or those who are not benefiting from olaparib treatment. Patients unable to follow study requirements or those who have access to olaparib through commercial sources in their location are not eligible.

Trial focus: The primary objective is to provide continued olaparib treatment to patients who are benefiting from therapy while monitoring ongoing safety and tolerability. The study tracks serious adverse events and adverse events of special interest for 30 days after the last dose, ensuring patient safety while maintaining treatment continuity.

Investigational drug: Olaparib is a PARP inhibitor administered orally in tablet or capsule form. It works by blocking the PARP enzyme involved in DNA repair, preventing cancer cells with BRCA mutations from repairing themselves. This leads to cancer cell death, particularly in tumors with homologous recombination deficiency.

Study of Abemaciclib and Letrozole for Patients with Estrogen Receptor Positive Low-Grade Serous Ovarian Cancer and Adult-Type Granulosa Cell Tumor

This trial evaluates the combination of abemaciclib and letrozole in treating patients with estrogen receptor-positive low-grade serous ovarian cancer or adult-type granulosa cell tumor. The study tests whether this hormone therapy combination can effectively control these rare, slow-growing gynecologic cancers.

Main inclusion criteria: Participants must have confirmed low-grade serous ovarian cancer or adult-type granulosa cell tumor with positive estrogen receptor expression. They need at least one measurable tumor lesion by RECIST v1.1 criteria or imaging. Patients must have received at least one prior line of platinum-based therapy with documented progression or intolerance. They must have an ECOG performance status of 0-1 and adequate organ function including normal blood counts, liver enzymes, and kidney function.

Main exclusion criteria: The trial excludes patients with active brain metastases, significant cardiovascular disease, uncontrolled infections, or other active cancers requiring treatment. Patients who received prior CDK4/6 inhibitor therapy or letrozole with progression are not eligible. Those with major surgery within 4 weeks or participation in other clinical trials within 4 weeks are excluded.

Trial focus: The study aims to determine the overall response rate of the abemaciclib-letrozole combination in these rare ovarian cancer types. Researchers will evaluate tumor response using RECIST v1.1 criteria, monitor progression-free survival, and assess quality of life using standardized questionnaires. Pre- and post-treatment biopsies and blood samples will be collected for biomarker analysis.

Investigational drugs: Abemaciclib is a CDK4/6 inhibitor taken orally that blocks proteins involved in cancer cell division. Letrozole is an aromatase inhibitor taken orally that reduces estrogen production in the body. Together, these medications work synergistically to slow cancer cell growth by targeting both cell cycle progression and hormone-dependent tumor growth.

Study of AZD8205 Alone or with Other Cancer Drugs for Patients with Advanced Breast, Biliary Tract, Ovarian, and Endometrial Cancer

This early-phase trial evaluates AZD8205 both as a single treatment and in combination with other anti-cancer therapies for patients with advanced solid tumors including breast, biliary tract, ovarian, and endometrial cancer. The study aims to determine the safest and most effective dose of AZD8205 for future research.

Main inclusion criteria: Participants must have confirmed advanced or metastatic solid tumors that have progressed after standard therapy or have no standard treatment options. They need at least one measurable lesion by RECIST v1.1 criteria and adequate organ and bone marrow function. Patients must have an ECOG performance status of 0-2, be 18 years or older, and have a life expectancy of at least 12 weeks. Those who can become pregnant must use effective contraception.

Main exclusion criteria: The trial excludes patients who have not recovered from previous treatments, those with uncontrolled brain metastases, patients with significant cardiovascular disease or uncontrolled infections, and those who are pregnant or breastfeeding. Patients with other cancers within the past 5 years (except certain skin cancers or cervical cancer in situ) are not eligible.

Trial focus: The study’s primary objectives are to evaluate the safety, tolerability, and pharmacokinetics of AZD8205. Researchers will monitor adverse events, changes in laboratory values and vital signs, and measure preliminary anti-tumor activity. The trial follows a dose-escalation design in Phase I, with expansion cohorts in Phase II to further assess safety and efficacy at recommended doses.

Investigational drug: AZD8205 is an investigational anti-cancer agent administered intravenously as a solution for infusion. It targets specific molecular pathways involved in tumor growth and survival, though the exact mechanism is under investigation. The drug represents a novel approach in targeted cancer therapy for multiple solid tumor types.

Study of AZD9574 and Temozolomide for Patients with Advanced Solid Tumors, Including Breast, Ovarian, Pancreatic, and Prostate Cancers

This trial evaluates AZD9574 both as monotherapy and in combination with temozolomide for treating advanced solid tumors with specific genetic mutations. The study focuses on cancers including IDH-mutant glioma, HER2-negative breast cancer, ovarian cancer, prostate cancer, and pancreatic cancer with BRCA or other homologous recombination repair mutations.

Main inclusion criteria: Participants must be 18 years or older with confirmed advanced cancer and specific genetic mutations (BRCA1/2, PALB2, RAD51C, or RAD51D). They need at least one measurable tumor lesion, an ECOG performance status of 0-2, and a life expectancy of at least 12 weeks. Patients must have progressing disease and adequate organ and bone marrow function. Female participants of childbearing potential must use effective contraception.

Main exclusion criteria: The trial excludes patients with uncontrolled brain metastases, major surgery within 4 weeks, significant cardiovascular disease, active infections, or other cancers within the past 5 years. Patients who are pregnant, breastfeeding, or unable to swallow oral medications are not eligible. Those with certain blood disorders, autoimmune diseases, or organ transplants are also excluded.

Trial focus: The study aims to determine the safety, tolerability, and optimal dosing of AZD9574 alone and with temozolomide. Researchers will evaluate preliminary anti-tumor activity, pharmacokinetics, and pharmacodynamics. The trial includes dose-escalation phases to establish maximum tolerated doses, followed by expansion cohorts to assess efficacy in specific tumor types.

Investigational drugs: AZD9574 is an oral investigational drug targeting specific pathways in cancer cells with genetic mutations. Temozolomide is a chemotherapy drug administered orally or intravenously that works with AZD9574 in combination therapy. Together, they aim to enhance treatment effectiveness against cancers with DNA repair deficiencies.

Study of DS-3939a for Patients with Advanced or Metastatic Solid Tumors

This early-phase trial evaluates DS-3939a for treating advanced or metastatic solid tumors including bladder, lung, breast, ovarian, bile duct, and pancreatic cancers. The study assesses the safety, tolerability, and preliminary effectiveness of DS-3939a at different dose levels to determine the recommended dose for future trials.

Main inclusion criteria: Participants must be 18 years or older with confirmed locally advanced, metastatic, or unresectable cancer. They need at least one measurable tumor lesion by RECIST v1.1 criteria and adequate organ function including heart (LVEF ≥50%), liver, kidney, and bone marrow. Patients must have an ECOG performance status of 0-1 and a life expectancy of at least 3 months. Specific cancer types are required for different study parts.

Main exclusion criteria: The trial excludes patients with active brain metastases, significant cardiovascular disease, uncontrolled hypertension, active infections, or other cancers requiring treatment. Those who underwent major surgery within 4 weeks, have inadequate organ function, or are pregnant/breastfeeding are not eligible. Patients with history of drug/alcohol abuse or certain infections are also excluded.

Trial focus: The study’s primary objectives are to evaluate safety, tolerability, and to determine the recommended dose for Part 2. Researchers will monitor adverse events, vital signs, ECGs, and laboratory parameters. The trial will assess objective response rate using RECIST v1.1 criteria and measure disease control rate, duration of response, and other efficacy endpoints.

Investigational drug: DS-3939a is an experimental medication administered intravenously as a solution for infusion. It is being studied for its potential to treat various solid tumors by targeting specific pathways that cancer cells use to grow and spread. The exact mechanism is under investigation as part of this early-phase clinical research.

Study of IMC-F106C alone and with checkpoint inhibitors in patients with advanced PRAME-positive cancers who have HLA-A*02:01

This Phase 1/2 trial evaluates IMC-F106C (brenetafusp) both as monotherapy and in combination with checkpoint inhibitors for treating advanced PRAME-positive cancers. The study focuses on patients with solid tumors who have the HLA-A*02:01 genetic marker and have progressed after standard therapies.

Main inclusion criteria: Participants must be 18 years or older with HLA-A*02:01 positive status and PRAME-positive tumors confirmed by testing. They need at least one tumor that can be biopsied and an ECOG performance status of 0-1. Patients must have measurable disease by RECIST v1.1 criteria, adequate organ function, stable brain metastases if present, and life expectancy exceeding 12 weeks. Cancer must be recurrent or refractory to standard treatments.

Main exclusion criteria: The trial excludes patients with prior PRAME-targeted therapy, active or untreated brain metastases, severe allergic reactions to antibody treatments, significant heart problems, active infections, known HIV/hepatitis infections, pregnancy/breastfeeding, other active cancers requiring treatment, major surgery within 4 weeks, participation in other trials within 4 weeks, severe kidney/liver problems, or conditions making participation unsafe.

Trial focus: Phase 1 aims to determine the safety, tolerability, and maximum tolerated dose of IMC-F106C via intravenous or subcutaneous administration. Phase 2 evaluates preliminary effectiveness using imaging techniques and RECIST v1.1 criteria. The study monitors cardiac activity, vital signs, blood tests, and assesses adverse events throughout treatment.

Investigational drug: IMC-F106C (brenetafusp) is an immunotherapy medication targeting PRAME proteins on cancer cells. It can be administered intravenously or subcutaneously and works by helping the immune system recognize and attack PRAME-positive cancer cells. This novel therapeutic represents a targeted immunotherapy approach for HLA-A*02:01-positive patients.

Summary

The 65 ongoing clinical trials for ovarian cancer demonstrate significant research activity across Europe, with trials concentrated in major countries including Germany, France, Spain, Italy, Belgium, and Poland. Several notable patterns emerge from these studies:

Treatment approaches: The trials span multiple treatment strategies including targeted therapies (PARP inhibitors like niraparib and olaparib), immunotherapies (checkpoint inhibitors, cancer vaccines), antibody-drug conjugates, and novel combination therapies. Many studies focus on maintenance therapy following initial chemotherapy response.

Patient populations: The trials address various patient subgroups including newly diagnosed advanced ovarian cancer, platinum-resistant disease, platinum-sensitive recurrent disease, and patients with specific genetic mutations (BRCA, HRD status). Several trials specifically target less common subtypes like low-grade serous ovarian cancer.

Geographic distribution: Belgium, Germany, France, Spain, and Italy host the most trials, providing broader access across Europe. Several Scandinavian countries (Denmark, Sweden, Norway, Finland) also participate in multiple studies. Some trials are conducted across 10+ European countries, maximizing patient access.

Drug development focus: Multiple trials evaluate PARP inhibitors (niraparib, olaparib, rucaparib), anti-angiogenic agents (bevacizumab), and novel immunotherapy approaches. Several studies test antibody-drug conjugates and targeted therapies against specific tumor markers. The emphasis on biomarker-selected populations reflects precision medicine approaches.

These trials offer hope for improved treatment options across the disease spectrum, from newly diagnosed to heavily pretreated patients, with particular attention to those with limited standard therapy options.

Ongoing Clinical Trials on Ovarian cancer

  • Study on Niraparib, Carboplatin, and Paclitaxel for Advanced Ovarian Cancer Patients After Tumor Removal

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Czechia Germany Italy Spain

  • Study on Olaparib and Durvalumab for Patients with Advanced Ovarian Cancer Undergoing Surgery

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany

  • Study of PC14586 for Patients with Advanced Solid Tumors with a Specific TP53 Mutation

    Recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    France Germany Italy Spain

  • Study Comparing Avutometinib and Defactinib with Other Treatments for Patients with Recurrent Low-Grade Serous Ovarian Cancer

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Denmark France Germany Ireland Italy +3

  • Study on the Effectiveness of Niraparib Rechallenge After Surgery in Ovarian Cancer Patients with Limited Metastasis

    Recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Spain

  • Study of Paclitaxel, Carboplatin, and Bevacizumab with Niraparib for Patients with Advanced Ovarian, Tubal, or Peritoneal Cancer After Surgery

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium France Italy Spain

  • Long-term Safety Study of Niraparib for Patients with Advanced Ovarian, Breast, or Prostate Cancer Who Completed a Previous Niraparib Study

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria France Germany Italy Romania Spain

  • Study of Abemaciclib and Letrozole for Patients with Estrogen Receptor Positive Low-Grade Serous Ovarian Cancer and Adult-Type Granulosa Cell Tumor

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium France The Netherlands

  • Study on Improving Ovarian Cancer Diagnosis Using Pyruvic Acid and Gadoteric Acid for Patients Suspected of Having Ovarian Cancer

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Denmark

  • Study on the Effectiveness and Safety of Cisplatin and Paclitaxel in Advanced Ovarian Cancer Patients After Surgery

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

More information about
Ovarian cancer:

Connected medications: